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Influence of Apoptosis and Cell Cycle Regulator Proteins on
Chemotherapy Response and Survival in Stage IIIA/IIIB
NSCLC Patients
Jose´ L. Morero, MD, Claudia Poleri, MD, Claudio Martı´n, MD, Maximiliano Van Kooten, MD,
Reynaldo Chaco´n, MD, and Moise´s Rosenberg, MD
Background: Prognosis for non-small cell lung cancer (NSCLC)
patients is very poor. Prediction of the response to treatment in
individual patients may be possible using molecular biological
alterations such as clinical biomarkers. We investigated the predic-
tive value of apoptosis and cell cycle regulator proteins for neoad-
juvant chemotherapy response in stage IIIA/IIIB NSCLC patients.
Methods: We evaluated p53, bcl-2, p21WAF1/CIP1, p27Kip1, and
Ki67 immunohistochemical expression and apoptotic index in me-
diastinal lymph node metastases from 23 IIIA and 10 IIIB NSCLC
patients before treatment with neoadjuvant platinum-based chemo-
therapy. Univariate analysis was performed to evaluate the relation-
ship between protein expression and survival or time to progression
(TTP).
Results: Median follow-up was 25 months (range, 4–112), median
TTP was 11 months (range, 0–112), and median overall survival
was 22 months (range, 4–112). Of 32 assessable patients, 18 (56%)
had stable disease, 12 (38%) had a PR, and two (6%) had progres-
sive disease. Of the 22 patients assessable for pN2 following
chemotherapy, 16 (77%) were positive. Univariate analysis showed
that shorter TTP correlated with progressive disease (p  0.000),
positive pN2 after chemotherapy (p  0.026), high Ki67 (p 
0.022), and high p21WAF1/CIP1 (p  0.038).
Conclusion: Our results suggest that in IIIA/IIIB NSCLC patients,
a high level of p21WAF1 expression in mediastinal lymph node
metastases before neoadjuvant platinum-based chemotherapy is as-
sociated with a poor outcome. Our results suggest that expression of
p21WAF1, which plays a role in preventing apoptosis, may be
significant when selecting chemotherapy for NSCLC patients.
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Despite major advances in cancer treatment, the prognosisfor patients with lung cancer has improved only mini-
mally. In early stages, surgery is the most efficient treatment;
however, only 55%–80% of stage I patients are alive at 5
years. Stage IIIA/B patients (N2–N3 metastatic lymph nodes)
have poor outcome, even with complete surgical resection;
5-year survival rates are 13% and 5%, respectively.1
Neoadjuvant chemotherapy has emerged as a strategy
to improve outcome in non-small cell lung cancer (NSCLC)
patients with regionally advanced disease, with varying re-
sults. Although neoadjuvant chemotherapy is not considered
standard treatment in stage IIIA yet, there are several papers
that explore this approach.2–5 The reason why patients receiv-
ing similar treatment have different responses and outcomes
is not well understood. Prediction of the response to treatment
in individual patients could be useful for better selection of
treatment strategy.
Apoptosis and cell cycle regulator alterations may have
predictive value in identifying appropriate strategies for pa-
tients. Cell proliferation and death cascades are very com-
plex, and, as a consequence, there are many proteins that may
be useful in predicting response to chemotherapy.6–10 Some
of these proteins can be identified in tumors by immuno-
histochemistry and may be useful in predicting chemother-
apy response and outcome in NSCLC patients. Immuno-
histochemistry avoids the complication of contamination
by nonneoplastic cells that constantly affects both Western
blot analysis and nucleic acid approaches. In addition, it is
a relatively easy method, suitable for routinely processed
samples.8
We selected p53, p21WAF1/CIP1, p27Kip1, and bcl-2
because they are significant cell cycle regulator proteins, with
controversial prognostic results.8–14
Wild-type p53 can block the progression of the cell
cycle and trigger apoptosis in response to DNA damage; p53
mutation promotes cellular proliferation and inhibits apopto-
sis. The half-life of the wild-type p53 proteins is short and
usually not detected by most immunohistochemical methods.
By contrast missense mutations in exons 5 to 8 are frequently
associated with prolonged half-life of the mutant protein and
its detection by immunohistochemical in lung cancers. Be-
cause of the simplicity of immunohistochemistry, it has been
widely used as a surrogate for p53 mutation status; however,
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the correlation is not exact. Meta-analysis showed that p53
protein overexpression studied in resected NSCLC tumors is
a poor prognostic factor, but most clinical pathologic studies
are performed in early-stage NSCLC, and in more advanced
stages, such studies are scant.8,15
p21WAF1/CIP1 is a multifunctional member of the
cyclin-dependent kinase inhibitory (CDKi) proteins, acti-
vated through p53-dependent or p53-independent pathways.
It plays an important role in the regulation of the cell cycle
and in preventing apoptosis. Prognostic impact of p21 is not
as intensively investigated as p53 in NSCLC tumors. Studies
in breast, gastric, endometrial, and head and neck cancers
showed contradicting results. High as well and low expres-
sion of p21 was correlated with a short patient survival.16 To
date, a consensus has not been reached concerning the prog-
nostic value of p21 in lung cancer11,13; p27Kip1 is another
member of the CDKi family, which regulates progression
from G1 to S phase.
Programmed cell death is regulated by members of the
bcl-2 family, normally associated with decreased apoptosis,
implying worse survival of patients with bcl-2–positive
NSCLC. However, contradictory results involving prognostic
impact are described.17
The aim of this study was to investigate the value of
apoptosis and cell cycle regulator proteins (p21WAF1,
p27Kip1, p53, bcl-2) in predicting progression and survival in
stage IIIA/IIIB NSCLC patients treated with neoadjuvant
chemotherapy. A secondary objective was to explore the
postchemotherapy expression of tumor markers in tissue
samples.
PATIENTS AND METHODS
Patients and Tumor Tissues
Clinical records were retrospectively reviewed of all
NSCLC patients with mediastinal lymph node metastases
(N2/3 status as determined by mediastinoscopy), treated at
Hospital Marı´a Ferrer and Instituto Alexander Fleming, Bue-
nos Aires, from 1996 to 2004. To be eligible for inclusion in
this study, patients were to have received two or three cycles
of neoadjuvant platinum-based chemotherapy, to have imag-
ing studies available for response evaluation, and to have
tissue available for immunohistochemistry. Patients were
required to have had at least 6 months follow-up.
Clinical response to neoadjuvant chemotherapy was
assessed according to World Health Organization criteria,
based on chest radiographs or computed tomography scans.
Patients with complete response, partial response (PR), or
stable disease (SD) were evaluated for tumor resection; when
surgical treatment was not possible, patients received radio-
chemotherapy. After progression, patients received various
chemotherapy regimens. Histologic types of tumors were
classified according to the 1999 World Health Organization
classification.
Immunohistochemistry
Immunohistochemical analyses were performed on pre-
chemotherapy samples collected from all eligible patients and
on postchemotherapy samples obtained from patients who
underwent complete resection or exploratory surgery post-
chemotherapy. All immunohistochemical analyses were car-
ried out on 10% formalin-fixed, paraffin-embedded tissue
sections cut to 5 m. The immunohistochemical method
(Histostain Plus, Zymed, South San Francisco, CA) used a
three-step indirect process based on the streptavidin-biotin
complex with peroxidase-conjugated streptavidin molecules,
and the substrate chromogen 3,3=-diaminobenzidine (Zymed).
The slides were counterstained with hematoxylin.
Mouse monoclonal antibodies (DAKO Corporation;
Carpinteria, CA) specific for p53 (clon DO7), bcl-2 (clon
100), Ki67 (clon MIB-1), p21WAF1/CIP1 (clon SX118), and
p27Kip1 (clon SX53G8) were used at dilutions and antigen
retrieval treatments recommended by the manufacturer and
positive and negative controls were performed.
Positive nuclear staining was demonstrated for all an-
tibodies, except for positive cytoplasmic staining for bcl-2
protein. We graded semiquantitatively in 10 high-power
fields, objective 40: p53, negative 10% and positive
10%; bcl-2, 0 (negative)  no staining, 1 (positive, low
expression)  1%–33%, 2 (positive, moderate expression) 
34%–66%, 3 (positive, high expression) 66%; Ki67: 0
(negative)  no staining, 1 (low expression)  1%–33%, 2
(moderate expression)  34%–66%, 3 (high expression)
66%; and p21WAF1/CIP1 and p27Kip1: low expression 
0%–25%, high expression  25%.
We marked Ki67 antigen with the MIB-1 antibody to
identify proliferating cells and determine the proliferation
index according the proportion of positive cells. The apopto-
tic index (AI) is defined here as the total number of apoptotic
cells and bodies counted in 10 high-power fields. According
to the median count of all pre- and postchemotherapy tumor
samples, we stratified in low AI when the count was less than
or equal to the median, and high AI when count was higher
than the median.8
Statistical Analyses
Statistical analysis was performed using the SPSS soft-
ware system (SPSS for Windows version 11.0, Chicago, IL).
Chi-square test and Fisher’s exact test were used to analyze
the association between categorical clinical, pathologic, and
molecular variables, and kappa and McNemar test to analyze
p53 and p21 agreement. We evaluated TTP from time of
mediastinoscopy to local progression or distant metastasis.
Patients who had not progressed were censored at the time of
last follow-up. Time-to-event curves were plotted using the
Kaplan-Meier method.
To analyze the mathematical relationship between ex-
pression of the cell cycle regulator proteins and survival or
TTP, we performed a univariate analysis (log-rank test). We
could not perform multivariate analyses because the sample
size underpowers this stringent test. A p value 0.05 was
considered to be significant.
All information obtained from patients’ records and
tissue samples was treated confidentially according to the
Declaration of Helsinki and International Conference on
Harmonisation Guidelines for Good Clinical Practice.
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RESULTS
Clinical Pathologic Findings
Our retrospective review identified 33 NSCLC patients
with histologically confirmed N2 or N3 mediastinal lymph
node metastases (Table 1). The majority of patients (82%)
were males, and 70% of patients had stage IIIA disease. All
patients received two to six cycles of platinum-based neoad-
juvant chemotherapy: 16 (49%) cisplatin-gemcitabine, nine
(27%) cisplatin-vinorelbine, and eight (24%) cisplatin-pacli-
taxel. No significant differences in response rates were seen
between different chemotherapy regimens.
All 33 patients reviewed were assessable for chemo-
therapy response except for one for whom no image was
available for re-evaluation. Of the 32 assessable patients, 30
(94%) had PR or SD and were thus assessed for suitability for
surgical resection; no complete clinical responses were ob-
served, and two patients progressed. Twenty-two patients
(67%) were considered suitable for surgery, three of whom
could undergo resection due to macroscopic residual invasion
of extrapulmonary tissues. Nineteen patients had complete
resection. Six of the 19 assessable patients (33%) with com-
plete resection had N pathologic down-staging, and one had
histologic complete response. Median follow-up in all 33
patients was 25 months (range, 4–112), median TTP was 11
months (range, 0–112), and median overall survival was 22
months (range, 4–112).
We studied metastases lymph node tissue samples from
33 patients before neoadjuvant chemotherapy (pre-chemo)
and from 18 patients after chemotherapy (post-chemo) and
from 15 patients with complete resection and three with
unresectable tumors. We excluded from post-chemo analyses
the patient with complete histologic response, and tissue
samples were unavailable for two patients.
The most frequent histologic type was adenocarcinoma
(73%, 24/33). Other histologic types were analyzed together
as nonadenocarcinomas and included seven patients with
squamous carcinoma, one with large cell carcinoma, and one
with adenosquamous carcinoma.
Twenty-two percent (7/32) of tumor samples showed high
proliferation (grade 3 Ki67 expression). The median AI was 31.
AI was low in 61% of pre-chemo tumors and high in 72% of
post-chemo tumors. This difference was not statically significant.
Immunohistochemistry
Tumor marker expression in metastatic lymph nodes
from NSCLC patient pre- and post-chemo tumor samples
is reported in Table 2. With the exception of bcl-2, all
markers were expressed less frequently in post-chemo
tumor samples than pre-chemo tumor samples; however,
this difference was not statistically significant when a
paired test using data from just the 18 post-chemo patients
was performed. There was no significant association be-
tween histologic type, AI, proliferation, and p53, p27, p21,
and bcl-2 expression, nor did we find agreement between
p53 and p21. Moreover, we found significant discordance:
14 p53 pre-QT–positive tumors had low p21 pre-chemo-
therapy expression. (  0.021, McNemar  0.013).
Clinical Factors, Tumor Marker Expression,
and TTP
We found no significant correlation between clinical
response and tumor marker expression (2 test, Fisher’s
exact test).
Univariate analysis was performed to evaluate the prog-
nostic value of the different clinicopathologic features of the
patients and the immunohistochemical parameters. Univari-
ate analysis suggested that TTP is influenced by clinical
response, positive pN post-chemo, and high pre-chemo ex-
pression of p21WAF1/CIP1 and/or Ki67 (Tables 3 and 4 ); no
post-chemo tumor markers had a significant correlation with
patient outcome, but post-chemo markers were only available
from PR/SD patients. We found that patients with better
clinical response had longer TTP: median TTP was 12 months in
TABLE 1. Patient Characteristics
Patients, no. (%) 33 (100)
Sex, no. (%)
Male 27 (82)
Female 6 (18)
Age, yr
Mean  SD 56  11
Range 25–73
Clinical stage, no. (%)
IIIA 23 (70)
IIIB 10 (30)
Clinical response (n  32), no. (%)
Assessable patients 32 (100)
Partial response 12 (38)
Stable disease 18 (56)
Progressive disease 2 (6)
Surgical intervention
Complete resection 19 (58)
Exploratory 3 (9)
None 11 (33)
pN (n  19), no. (%)
Positive 13 (68)
Negative 6 (32)
pN, Mediastinal lymph node pathological status.
TABLE 2. Frequency of Tumor Markers
Pre-chemo Post-chemo
p53
Positive 24/32 (75%) 9/18 (50%)
p21
High 13/33 (41%) 3/18 (17%)
p27
High 21/33 (64%) 6/18 (33%)
bcl-2
Positive 3/33 (9%) 3/18 (17%)
Ki67
High 7/32 (22%) 2/18 (11%)
See Materials and Methods for definitions of positive/high.
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PR patients, 9 months in SD patients, and 2 months in PD
patients (p 0.000). From the 30 patients who had PR/SD after
neoadjuvant chemotherapy, 19 with complete resection had a
median TTP of 12 months, whereas 11 nonresected patients had
a median TTP of 9 months (p  0.09).
There was a significant difference in TTP between
patients who were pN negative and patients who were pN
positive following chemotherapy. The median TTP was not
reached in the pN-negative post-chemo cohort, whereas the
median TTP in the pN-positive post-chemo group was 11
months (p  0.026).
The median TTP of patients with a high AI post-chemo
was 10 months, and with low AI post-chemo tumors, it was
20 months, but this difference was not statistically significant.
The expression of molecular markers in post-chemo tumor
samples had no significant association with TTP. However, a
correlation was observed between pre-chemo expression of
p21 and TTP and between pre-chemo Ki67 and TTP. Patients
with high levels of Ki67 expression in metastatic lymph
nodes before neoadjuvant chemotherapy had a lower median
TTP than that observed in patients with low and moderate
expression (Figure 1). Similar results were seen with pre-
chemo p21 expression: the median TTP of patients with high
pre-chemo p21 expression was 9 months, all these patients
experiencing progressive disease by 17 months; in contrast,
44% of patients with low pre-chemo p21 expression had not
progressed at this time (Figure 2).
We analyzed together both significant markers: Ki67
and p21 expression. We found that the group of patients with
low Ki67 and low p21 pre-chemo tumor expression had a
long median TTP (17 months), and all patients who were
alive and had not progressed (5/32) had low p21 and low
Ki67 pre-chemo (log-rank test, p  0.003).
When we did univariate analysis between molecular
markers, clinical factors, and overall survival, we did not find
any significant association.
DISCUSSION
NSCLC patients show diverse responses to neoadju-
vant chemotherapy. Translation of recent advances in under-
standing the molecular and cellular pathology into patient
TABLE 3. Univariate Analysis of Clinical and Pathologic
Factors (Log-Rank Test)
Factors Categories p
Stage IIIA/IIIB 0.959
Histologic type Adeno-/nonadenocarcinoma 0.512
Clinical response PR/SD/PD 0.000
Surgical resectiona Yes/no 0.09
pN post-chemo Positive/negative 0.026
a Only SD/PR patients (30/33) are included.
PR, partial response; SD, stable disease; PD, progressive disease; pN, Mediastinal
lymph node pathological status.
TABLE 4. Univariate Analysis of the Predictive Value of
Molecular Markers in Relation to Time to Progression
Markers Categories
p
Pre-chemo Post-chemo
p27 High/low 0.251 0.397
p21 High/low 0.038 0.961
p53 Positive/negative 0.658 0.726
Ki67 High/moderate-low 0.022 0.054
Bcl-2 Positive/negative 0.610 0.794
Apoptotic index High/low 0.122 0.073
FIGURE 1. Time to progression with respect to Ki67
pre-QT expression (high, 7/32 patients; low/moderate,
25/32 patients).
FIGURE 2. Time to progression with respect to p21 pre-
chemo expression (high, 13/33 patients; low, 20/33).
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benefit could explain these diverse responses. To this end, we
retrospectively explored the potential predictive and prognos-
tic value of tumor markers in pre-chemo metastatic medias-
tinal lymph nodes and examined changes induced by chemo-
therapy in resected tumors.
In this group of IIIA-IIIB NSCLC patients treated with
induction chemotherapy, we found that patients with SD or
PR and/or negative post-chemo pN have longer TTP, as
previously reported in others studies.18,19 There are no well-
established criteria to assess the value of induction therapy
(overall efficacy). TTP seems to be a more reliable parameter
when the efficacy of neoadjuvant chemotherapy is explored.
Moreover, TTP likely has a significant impact on the quality
of life of patients.18 In our series after the progression, the
patients received diverse treatment; for this reason, the over-
all survival hardly reflects the benefits of induction chemo-
therapy in this heterogeneous population.
We consider that the patients who responded to neoad-
juvant chemotherapy and received surgical treatment have a
higher probability of a better outcome, and molecular mark-
ers of cell proliferation and apoptosis could be useful for
identifying such patients.
This study shows that high expression of p21 is a
significant factor in predicting a poor outcome in stage
IIIA/IIIB NSCLC patients treated with neoadjuvant chemo-
therapy. High pre-chemo expression of p21 is associated with
early disease progression: 50% of these patients had pro-
gressed at 9 months and all of them had progressed by 17
months.
Other studies have shown that high p21 expression is an
independent and significant favorable prognostic factor in
early-stage NSCLC patients treated with surgery only, inter-
preting these results by the inhibitory cell proliferation p21
function.13,20 These apparently contradictory results could be
explained in terms of the multiple functions of p21. On the
one hand, the ability of p21 to inhibit cell proliferation may
contribute to its ability to act as tumor suppressor. Although
mutations in p21 are extremely rare, p21 knockout mice
develop spontaneous tumors, showing the importance of this
gene in tumor suppression and oncogenes that repress p21
promote cell growth and tumorigenesis.21 Conversely, p21 is
a major inhibitor of apoptosis.11,22 DNA damage and oxida-
tive stress activate two pathways: one involving p53-depen-
dent apoptosis and the other involving p53-independent ac-
tivation of p21 that protects cells from apoptosis and allows
cells to repair damage to continue cell division. We propose
that the poor outcome demonstrated in this study for patients
with high p21 expression in lymph nodes before neoadjuvant
chemotherapy is due to the predominant antiapoptotic effects
of this multifunctional protein in the complex cell cycle
cascade. Anticancer chemotherapy involves triggering tumor
cells to undergo apoptosis, so apoptosis-resistant cells would
be refractory to such therapy. Platinum and other DNA
cross-linking agents kill cancer cells by inducing p53-depen-
dent and p53-independent apoptosis. p21 is an important
downstream protein in the p53 pathway that could protect
proliferating cells from apoptosis induced by DNA cross-
linking agents, inducing chemotherapy resistance. Absence of
p21 results in enhanced chemosensitivity to DNA-damaging
agents both in vitro and in vivo.23,24 For example, p21-
deficient cell lines display an increased sensitivity to apopto-
sis induced by DNA-damaging agents or irradiation.25 Our
study indicated that significant discordance between p21
status and p53 status, which was consistent with the results of
other clinical studies, may be due to the activation of p21
through p53-independent pathways.20 We also found that
tumors with a high proliferation rate (high Ki67 expression)
were associated with early recurrence, indicating their ag-
gressive behavior. In this group of advanced NSCLC patients
treated with neoadjuvant chemotherapy, there was no signif-
icant correlation between p53, bcl-2, and TTP; similar results
were found by Tanaka et al.26 in stage IIIA NSCLC patients
without any preoperative therapy.
In view of the results suggesting that pre-chemo sam-
ples have prognostic value in predicting response to treat-
ment, we extended our study to post-chemo samples. We
found no significant change in marker expression levels
between pre-chemo and post-chemo tumor samples, but post-
chemo markers were only available from PR/SD patients and
tumor marker expression in post-chemo samples did not show
any significant correlation with TTP. Unexpectedly, tumors
with high AI behave more aggressively; patients with a high
AI after chemotherapy progressed earlier than those with low
AI (10 versus 20 months); this may be related to more active
tumor proliferation.27–31
In support of the idea that clinical characteristics and
molecular biomarker alteration could predict chemotherapy
response and TTP, we found that of the seven of 33 patients
alive and without disease progression all had low pre-chemo
expression of p21 and Ki67.
CONCLUSION
Our results suggest that stage IIIA/IIIB NSCLC patients
with high p21WAF1 expression in metastatic mediastinal lymph
nodes before treatment with neoadjuvant platinum-based che-
motherapy have a significantly poorer outcome than those with
low p21 expression, resulting in a significant predictive factor of
a short TTP. Analysis of p21WAF1/CIP1 expression in tumor
cells could have importance as other cellular proteins in the
selection of treatment for patients with lung cancer. Because
p21-overexpressed cancer cells are able to escape a chemother-
apeutic death by repairing their damaged DNA, transiently p21
inhibitor molecules in combination with standard chemotherapy
hold considerable promise in improving patient outcome.11
Understanding the mechanisms of inherent drug resis-
tance has important clinical implications with respect to the
selection of patients who may benefit from specific chemo-
therapeutic agents.
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